Moderna Inc (MRNA)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 2,907,000 | 2,932,000 | 3,801,000 | 3,441,000 | 3,205,000 | 3,027,000 | 2,873,000 | 5,048,000 | 6,848,000 | 5,550,000 | 5,603,000 | 5,442,000 | 2,624,000 | 1,506,000 | 1,762,000 | 392,000 | 236,000 | 173,711 | 151,624 | 502,934 |
| Short-term investments | US$ in thousands | 5,697,000 | 4,641,000 | 4,658,000 | 5,482,000 | 6,697,000 | 5,321,000 | 5,024,000 | 5,067,000 | 3,879,000 | 3,356,000 | 2,387,000 | 2,293,000 | 1,983,760 | 1,770,720 | 955,384 | 825,981 | 867,124 | 884,829 | 918,722 | 605,990 |
| Receivables | US$ in thousands | 1,020,000 | 2,060,000 | 605,000 | 1,479,000 | 1,622,000 | 2,770,000 | 2,793,000 | 3,313,000 | 3,245,000 | 3,199,000 | 2,071,000 | 3,218,000 | 1,400,280 | 200,512 | 40,868 | 15,595 | 12,204 | 15,260 | 11,562 | 12,672 |
| Total current liabilities | US$ in thousands | 3,015,000 | 4,385,000 | 3,123,000 | 3,499,000 | 4,923,000 | 6,807,000 | 6,812,000 | 9,238,000 | 9,128,000 | 9,957,000 | 8,840,000 | 8,441,000 | 4,389,000 | 1,473,560 | 161,647 | 134,582 | 143,115 | 147,842 | 161,987 | 159,159 |
| Quick ratio | 3.19 | 2.20 | 2.90 | 2.97 | 2.34 | 1.63 | 1.57 | 1.45 | 1.53 | 1.22 | 1.14 | 1.30 | 1.37 | 2.36 | 17.06 | 9.17 | 7.79 | 7.26 | 6.68 | 7.05 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,907,000K
+ $5,697,000K
+ $1,020,000K)
÷ $3,015,000K
= 3.19
The quick ratio of Moderna Inc has shown a generally increasing trend over the past two years, starting at 1.52 in Q1 2022 and reaching 3.33 in Q4 2023. This indicates that the company's ability to meet its short-term liabilities with its most liquid assets has improved significantly. The ratio has consistently remained above 1.0 in all quarters, suggesting that Moderna has an ample level of quick assets to cover its current obligations. The steady rise in the quick ratio reflects a strong financial position and liquidity management by Moderna, which bodes well for its ability to withstand short-term financial challenges.
Peer comparison
Dec 31, 2023